/
Oncology
Locally Advanced/metastatic Solid Tumors
10
Pipeline Programs↗
10
Active Trials↗
7
Companies Involved↗
Locally Advanced/Metastatic Solid Tumors is an early-stage landscape with 10 programs across 7 companies. The most active players are Bliss Biopharmaceutical (Hangzhou) Co., Ltd, Proviva Therapeutics, Inc., Jiangsu Simcere Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 15
Phase 23
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
13
clinical trials
Recruiting10 · 77%
Unknown status3 · 23%
Clinical Trials
Trial Activity
13 trials
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Recruiting·—·Phase 1/2·NCT05699811·40 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)